Condition: Breast Cancer · Breast-conserving Surgery · Breast Cancer - Infiltrating Ductal Carcinoma · Sponsor: Innoblative Designs, Inc.
This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.
This description comes directly from the study's public registry record.
Clinical Trials Manager · 833-920-4660 · kathy@innoblative.com
VP Quality Assurance & Regulatory Affairs · 833-920-4660 · kcrowley@innoblative.com
Always discuss trial participation with your own doctor first.
| University of Texas Medical Branch at Galveston, TX | Galveston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07206121